Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in RLAY.
← Back to Free Index

RLAY

Analysis as of: 2026-02-20
Relay Therapeutics, Inc.
Clinical-stage biotech developing small-molecule therapies for cancer and genetic disease using its Dynamo computational+experimental discovery platform.
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Pivotal-gated oncology option with workflow moat potential
A single Phase 3 program can flip this from pre-revenue optionality to a commercial oncology franchise by 2031. Upside depends on clear differentiation and building testing-to-therapy pathways that make adoption the default.

Analysis

Thesis
If zovegalisib clears its pivotal gate and launches on-time, RLAY can turn AI-enabled discovery + an FDA-accelerated path into a durable PI3K franchise, then defend share via testing→therapy workflow partnerships and a proprietary combo strategy; failure reverts value toward cash-minus-burn.
Last Economy Alignment
Cheaper compute speeds small-molecule iteration and regimen design, but value is still gated by Phase 3 and FDA outcomes; defensibility comes from IP + clinical datasets more than “software.”
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
5.8x (from 5 most recent analyses)
Reasoning
RLAY is a step-function setup: moving from “clinical option value” to “launchable oncology franchise” can re-rate the stock quickly. Upside is amplified if it builds distribution rails (testing→therapy initiation + outcomes capture) that reduce friction and defend adoption as competitors and formularies optimize.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The binding constraint is Phase 3-quality differentiation and a clean label versus capivasertib-based alternatives. Secondary risks are multi-year timeline slip (enrollment/events/DB lock), dilution if burn stays high into launch, and payer/clinical inertia if benefit-risk is only incremental.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.28
They use cheap compute to iterate drug designs faster, but the real control point is still the FDA gate and the clinical dataset that proves differentiation. If they also own the “testing → start therapy → measure outcomes” workflow, competitors have a harder time displacing them even with similar science.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$14.70
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case